Other observed topics

phase

Observed in 126 articles across 31 journals.

Falling

Latest share0.26%

Change vs baseline-0.11 pp

Months observed12

Latest monthJul 2026

Portfolio article share

Attention over this snapshot

13 monthly points

Journal breadth

Where it appears

Journal for ImmunoTherapy of Cancer46
BMJ Open24
Gut9
Lupus Science & Medicine7
European Journal of Hospital Pharmacy4
Journal of Scleroderma and Related Disorders4
BMJ Open Ophthalmology3
BMJ2
BMJ Neurology Open2
BMJ Open Respiratory Research2
RMD Open2
Thorax2

Co-occurrence

Explore nearby topics

Inspect the source signal

Article evidence

30 high-ranking examples

Journal for ImmunoTherapy of Cancer · 2025-11-07

1341 A phase 1b/2 study of nelmastobart with capecitabine in patients with refractory mCRC

Phrase rank #1 · DOI 10.1136/jitc-2025-SITC2025.1341

European Journal of Hospital Pharmacy · 2025-10-24

Pharmaceutical care in the screening process of phase I oncohaematological clinical trials

Phrase rank #1 · DOI 10.1136/ejhpharm-2024-004168

BMJ Open · 2026-06-02

Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol

Phrase rank #2 · DOI 10.1136/bmjopen-2025-115731

BMJ Open Respiratory Research · 2026-03-10

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial

Phrase rank #2 · DOI 10.1136/bmjresp-2024-002937

Journal for ImmunoTherapy of Cancer · 2025-11-07

1316 Initial monotherapy clinical activity of invikafusp alfa, a first-in-class TCR β-chain-targeted bifunctional antibody, in tissue-agnostic, TMB-H patients from STARt-001, a phase 1/2 trial

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.1316

Journal for ImmunoTherapy of Cancer · 2025-11-04

587 Phase 1b/2 dose escalation and expansion study of STC-15, a METTL3 inhibitor, in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0587

Journal for ImmunoTherapy of Cancer · 2025-11-04

549 Phase 2 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in combination with pembrolizumab in patients with head and neck squamous cell carcinoma

Phrase rank #2 · DOI 10.1136/jitc-2025-SITC2025.0549

BMJ Open · 2025-10-15

Barriers and enablers to medical students’ engagement in research and clinical academic careers: a mixed-methods study

Phrase rank #2 · DOI 10.1136/bmjopen-2025-102988

BMJ Open · 2025-10-07

Self-advocacy in stroke patients in China: a mixed-methods analysis

Phrase rank #2 · DOI 10.1136/bmjopen-2025-099555

Gut · 2026-06-23

O80 Withdrawal time and CADe are independent predictors of adenoma detection rate: result from a national prospective study

Phrase rank #3 · DOI 10.1136/gutjnl-2026-BSG.79

Journal for ImmunoTherapy of Cancer · 2025-11-04

490 Laser interstitial thermal therapy plus pembrolizumab extends survival and ignites anti-tumor immunity in recurrent high-grade astrocytoma: results from a phase 1/randomized phase 2b trial

Phrase rank #3 · DOI 10.1136/jitc-2025-SITC2025.0490

Journal of Scleroderma and Related Disorders · 2026-06-05

P.202 Raynaud’s phenomenon and systemic sclerosis: differences in microcirculatory adaptive changes to cold exposure

Phrase rank #4 · DOI 10.1136/JSRD-2026-SSWC.246

British Journal of Sports Medicine · 2026-04-29

Injury risk and its relationship with biological maturation among 100 junior tennis athletes: a 15-year retrospective analysis

Phrase rank #4 · DOI 10.1136/bjsports-2025-110713

BMJ Neurology Open · 2026-03-24

Two phase 1 randomised studies investigating the safety and pharmacokinetics of bepranemab in healthy participants of different ethnicities

Phrase rank #4 · DOI 10.1136/bmjno-2025-001395

Lupus Science & Medicine · 2026-03-01

PO:13:341 Core curriculum for self-management education in sle: insights from empodera-les program

Phrase rank #4 · DOI 10.1136/lupus-2026-el.388

Heart · 2025-12-08

P22 Ascertaining the effect of phase 1 cardiac rehabilitation on re-hospitalisations

Phrase rank #4 · DOI 10.1136/heartjnl-2025-BACPR.31

BMJ Supportive & Palliative Care · 2025-11-21

P-86 Setting up human factors-based simulation at the hospice – a pragmatic approach

Phrase rank #4 · DOI 10.1136/spcare-2025-HUK.103

Journal for ImmunoTherapy of Cancer · 2025-11-07

1344 AgenT-797, an allogeneic iNKT cell therapy, demonstrates durable clinical activity in solid tumors: updated phase 1 findings

Phrase rank #4 · DOI 10.1136/jitc-2025-SITC2025.1344

Journal for ImmunoTherapy of Cancer · 2025-11-07

1313 Nelmastobart combination shows excellent tolerability and early antitumor activity in refractory mCRC

Phrase rank #4 · DOI 10.1136/jitc-2025-SITC2025.1313

BMJ Open · 2026-05-12

Development and validation of a community-reported outcome measure of the value of school-based screening programmes for Indigenous populations: a mixed-methods study protocol

Phrase rank #5 · DOI 10.1136/bmjopen-2025-111701

BMJ Open · 2026-01-09

CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial

Phrase rank #5 · DOI 10.1136/bmjopen-2024-086005

Journal of Neurology, Neurosurgery & Psychiatry · 2025-11-26

158 Efficacy and safety of rimegepant for the prevention of migraine in Japan

Phrase rank #5 · DOI 10.1136/jnnp-2025-ABN.158

Journal for ImmunoTherapy of Cancer · 2025-11-07

1317 AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma

Phrase rank #5 · DOI 10.1136/jitc-2025-SITC2025.1317

Journal for ImmunoTherapy of Cancer · 2025-11-07

1334 Preliminary safety, pharmacokinetics, pharmacodynamics, and efficacy of FL115, a novel IL-15 superagonist, from a phase 1 study in patients with advanced solid tumors

Phrase rank #5 · DOI 10.1136/jitc-2025-SITC2025.1334

Journal for ImmunoTherapy of Cancer · 2025-11-04

496 CD47 expression as a predictive biomarker for evorpacept in HER2-positive gastric/gastroesophageal cancer from the Phase 2 randomized ASPEN-06 trial

Phrase rank #5 · DOI 10.1136/jitc-2025-SITC2025.0496

Journal for ImmunoTherapy of Cancer · 2025-11-04

573 Phase 1 study of GEN2, a personalizing systemic cancer immunotherapy, in adult patients with advanced solid tumor malignancies

Phrase rank #5 · DOI 10.1136/jitc-2025-SITC2025.0573

BMJ Open · 2025-09-26

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol

Phrase rank #5 · DOI 10.1136/bmjopen-2025-100241

Gut · 2026-06-23

P3 A Nationwide study of artificial intelligence in adenoma detection during colonoscopy - final result from the NAIAD trial

Phrase rank #6 · DOI 10.1136/gutjnl-2026-BSG.142

Journal for ImmunoTherapy of Cancer · 2026-03-27

CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study

Phrase rank #6 · DOI 10.1136/jitc-2025-012208

BMJ Paediatrics Open · 2026-03-13

Development, implementation and short-term impact of capacity building workshops on nurturing care for paediatricians across India: a triphasic mixed-methods study

Phrase rank #6 · DOI 10.1136/bmjpo-2025-003800